BELLEIN LIMITED – Trademark Portfolio

Entity Type: 99

BELLEIN LIMITED holds 4 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 3 filings in this category. The portfolio also extends into Class 27 (Floor Coverings) across 2 Nice Classification classes. Currently, 3 trademarks are registered and 1 is pending. Notable registered marks include PURESTVITS, PETS PUREST, and GLP-1 PUREST. The owner is based in KOK TSUI.

RM 509, 5/F THE CLOUD

111 TUNG CHAU ST TAI

KOK TSUI 999077 , HK

4 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

BELLEIN LIMITED's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (3 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

27
Floor Coverings (1 filing)

Carpets, rugs, mats and matting, linoleum and other materials for covering floors

Frequently Asked Questions

How many trademarks does BELLEIN LIMITED have?

BELLEIN LIMITED has 4 U.S. trademarks filed with the USPTO. Of these, 3 registered, 1 pending.

What trademark classes does BELLEIN LIMITED file in?

BELLEIN LIMITED files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 27 (Floor Coverings). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are BELLEIN LIMITED's most well-known trademarks?

BELLEIN LIMITED's registered trademark portfolio includes well-known marks such as PURESTVITS, PETS PUREST, and GLP-1 PUREST. These are among 3 currently registered trademarks in the portfolio.

What is BELLEIN LIMITED's trademark registration success rate?

BELLEIN LIMITED has a 100% trademark registration rate, with 3 out of 3 resolved applications resulting in successful registration. Currently, 1 application is pending review.